158 related articles for article (PubMed ID: 23059763)
1. Small molecule agents targeting the p53-MDM2 pathway for cancer therapy.
Wang W; Hu Y
Med Res Rev; 2012 Nov; 32(6):1159-96. PubMed ID: 23059763
[TBL] [Abstract][Full Text] [Related]
2. An overview of PROTACs targeting MDM2 as a novel approach for cancer therapy.
Li H; Cai X; Yang X; Zhang X
Eur J Med Chem; 2024 Jun; 272():116506. PubMed ID: 38761584
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule correctors and stabilizers to target p53.
Fallatah MMJ; Law FV; Chow WA; Kaiser P
Trends Pharmacol Sci; 2023 May; 44(5):274-289. PubMed ID: 36964053
[TBL] [Abstract][Full Text] [Related]
4. Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists.
Czarna A; Beck B; Srivastava S; Popowicz GM; Wolf S; Huang Y; Bista M; Holak TA; Dömling A
Angew Chem Int Ed Engl; 2010 Jul; 49(31):5352-6. PubMed ID: 20575124
[No Abstract] [Full Text] [Related]
5. MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future.
Wang W; Albadari N; Du Y; Fowler JF; Sang HT; Xian W; McKeon F; Li W; Zhou J; Zhang R
Pharmacol Rev; 2024 May; 76(3):414-453. PubMed ID: 38697854
[TBL] [Abstract][Full Text] [Related]
6. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting.
Hernández Borrero LJ; El-Deiry WS
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188556. PubMed ID: 33932560
[TBL] [Abstract][Full Text] [Related]
7. Molecularly targeted therapies for p53-mutant cancers.
Zhao D; Tahaney WM; Mazumdar A; Savage MI; Brown PH
Cell Mol Life Sci; 2017 Nov; 74(22):4171-4187. PubMed ID: 28643165
[TBL] [Abstract][Full Text] [Related]
8. Activity-Directed Synthesis: A Flexible Approach for Lead Generation.
Karageorgis G; Liver S; Nelson A
ChemMedChem; 2020 Oct; 15(19):1776-1782. PubMed ID: 32734671
[TBL] [Abstract][Full Text] [Related]
9. MDM2, MDMX and p53 in oncogenesis and cancer therapy.
Wade M; Li YC; Wahl GM
Nat Rev Cancer; 2013 Feb; 13(2):83-96. PubMed ID: 23303139
[TBL] [Abstract][Full Text] [Related]
10. Small-molecule MDM2-p53 inhibitors: recent advances.
Zhang B; Golding BT; Hardcastle IR
Future Med Chem; 2015; 7(5):631-45. PubMed ID: 25921402
[TBL] [Abstract][Full Text] [Related]
11. Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities.
Hong B; van den Heuvel AP; Prabhu VV; Zhang S; El-Deiry WS
Curr Drug Targets; 2014 Jan; 15(1):80-9. PubMed ID: 24387333
[TBL] [Abstract][Full Text] [Related]
12. MDM2-p53 pathway in hepatocellular carcinoma.
Meng X; Franklin DA; Dong J; Zhang Y
Cancer Res; 2014 Dec; 74(24):7161-7. PubMed ID: 25477334
[TBL] [Abstract][Full Text] [Related]
13. Targeting p53-MDM2-MDMX loop for cancer therapy.
Zhang Q; Zeng SX; Lu H
Subcell Biochem; 2014; 85():281-319. PubMed ID: 25201201
[TBL] [Abstract][Full Text] [Related]
14. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
Ding Q; Zhang Z; Liu JJ; Jiang N; Zhang J; Ross TM; Chu XJ; Bartkovitz D; Podlaski F; Janson C; Tovar C; Filipovic ZM; Higgins B; Glenn K; Packman K; Vassilev LT; Graves B
J Med Chem; 2013 Jul; 56(14):5979-83. PubMed ID: 23808545
[TBL] [Abstract][Full Text] [Related]
15. Chemo-/Regio-Selective Synthesis of Novel Functionalized Spiro[pyrrolidine-2,3'-oxindoles] under Microwave Irradiation and Their Anticancer Activity.
Sharma R; Yadav L; Nasim AA; Yadav RK; Chen RH; Kumari N; Ruiqi F; Sharon A; Sahu NK; Ippagunta SK; Coghi P; Wong VKW; Chaudhary S
Molecules; 2023 Sep; 28(18):. PubMed ID: 37764279
[TBL] [Abstract][Full Text] [Related]
16. Study of
Biswas P; Bibi S; Yousafi Q; Mehmood A; Saleem S; Ihsan A; Dey D; Hasan Zilani MN; Hasan MN; Saleem R; Awaji AA; Fahmy UA; Abdel-Daim MM
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049742
[TBL] [Abstract][Full Text] [Related]
17. Hesperidin Inhibits the p53-MDMXInteraction-Induced Apoptosis of Non-Small-Cell Lung Cancer and Enhances the Antitumor Effect of Carboplatin.
Feng Y; Huo H; Tang Q
J Oncol; 2022; 2022():5308577. PubMed ID: 36157229
[TBL] [Abstract][Full Text] [Related]
18. Tetrahydropyridines' Stereoselective Formation, How Lockdown Assisted in the Identification of the Features of Its Mechanism.
Vereshchagin AN; Iliyasov TM; Karpenko KA; Akchurin RN; Minyaev ME
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889242
[TBL] [Abstract][Full Text] [Related]
19. PROTAC Degraders with Ligands Recruiting MDM2 E3 Ubiquitin Ligase: An Updated Perspective.
Han X; Wei W; Sun Y
Acta Mater Med; 2022; 1(2):244-259. PubMed ID: 35734447
[TBL] [Abstract][Full Text] [Related]
20. Comparative Dynamic Features of Apo and Bound MDM2 Protein Reveal the Mechanism of Inhibitor Recognition for Anti-Cancer Activity.
I El Habbash A; El Rashedy A; Soliman MES
Curr Med Chem; 2023; 30(10):1193-1206. PubMed ID: 35702782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
